The latest price target for Summit Therapeutics (NASDAQ:SMMT) was reported by HC Wainwright & Co. on September 17, 2024. The analyst firm set a price target for $45.00 expecting SMMT to rise to within 12 months (a possible 79.78% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Summit Therapeutics (NASDAQ:SMMT) was provided by HC Wainwright & Co., and Summit Therapeutics reiterated their buy rating.

There is no last upgrade for Summit Therapeutics

There is no last downgrade for Summit Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Summit Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Summit Therapeutics was filed on September 17, 2024 so you should expect the next rating to be made available sometime around September 17, 2025.

While ratings are subjective and will change, the latest Summit Therapeutics (SMMT) rating was a reiterated with a price target of $45.00 to $45.00. The current price Summit Therapeutics (SMMT) is trading at is $25.03, which is out of the analyst’s predicted range.